Myriad Genetics Stock
Myriad Genetics Stock
We can see a decrease in the price for Myriad Genetics. Compared to yesterday it has lost -€0.080 (-2.200%).
With 7 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
Based on the current price of 3.56 € the target price of 8 € shows a potential of 124.72% for Myriad Genetics which would more than double the current price.
Criterium "EBIT growth" is seen as the biggest plus for Myriad Genetics stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Myriad Genetics in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Myriad Genetics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Myriad Genetics | -2.200% | -4.813% | -27.935% | -73.824% | -32.830% | -79.446% | -84.966% |
| Healthequity Inc. | -0.760% | 6.504% | -7.092% | -36.408% | -16.026% | 6.504% | 0.000% |
| Bruker Corp. | 3.110% | 9.925% | -21.202% | -30.918% | -17.725% | - | - |
| Omnicell Inc. | -1.760% | 10.596% | -21.596% | -10.695% | -13.918% | -33.200% | -67.885% |
Comments
Myriad Genetics (NASDAQ:MYGN) had its price target lowered by analysts at Piper Sandler from $9.00 to $8.50. They now have an "overweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at Piper Sandler from $12.50 to $9.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat
Myriad Genetics, Inc. (NASDAQ: MYGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $14.00 to $8.00. They now have a "buy" rating on the stock.
Show more
Ratings data for MYGN provided by MarketBeat